Opinion|Videos|December 5, 2025
Payer and Prior Authorization Barriers
Panelists discuss how payer controls and prior authorization policies delay and derail LDL-lowering therapy.
Advertisement
Episodes in this series
Panelists discuss how payer utilization management and prior authorization processes delay therapy initiation and contribute to high abandonment rates.
The paperwork burden discourages prescribers and frustrates patients, often interrupting continuity of care. Panelists highlight that these barriers disproportionately affect lower-income populations and smaller practices.
They recommend policy reforms that balance cost control with clinical flexibility, enabling timely treatment for high-risk individuals.
Advertisement
Related to this article
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy
2
Precision Drugs Meet Payer Realities
3
Cleveland Clinicians Say Obesity Care Starts Too Late for Many Patients
4
GOLD COPD Conference Turns to Earlier Diagnosis and Proactive Care
5